MPA Meningioma Risk: Key Insights and Implications

By Crystal Lubbe

January 22, 2025

The South African Health Products Regulatory Authority (SAHPRA) has issued a clarification regarding the benefits and risks associated with medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone. This substance is used for contraception, managing endometriosis-associated pain, and treating certain cancers. SAHPRA has updated the safety warnings for MPA-containing products to include the potential MPA meningioma risk based on epidemiological studies conducted in France and the United States.

Key Insights

SAHPRA identified an increased risk of meningioma associated with prolonged use of MPA. Although the absolute risk remains low, only 32 cases have been reported globally over the past 20 years. MPA appears in various products, such as Depo-Provera, Provera, Petogen, Medroxyprogesterone Mylan, Sayana, Omrastoz, Trivina, and Triclogyn. Healthcare professionals commonly prescribe these products for contraception, managing endometriosis, and providing palliative care for certain cancers. Providers should monitor patients for signs of meningioma and stop MPA use if diagnosed, particularly when used for non-oncological reasons. Patients should discuss potential side effects with their healthcare providers. SAHPRA also urges the public and healthcare professionals to report any suspected adverse drug reactions related to MPA.

Background Context

This update stems from regulatory actions in Europe, prompted by studies identifying an increased risk of meningioma with prolonged MPA use. Similar risks were observed with other progestogens, such as medrogestone and promegestone, though these are not currently marketed in South Africa. Meningiomas are typically benign tumors that develop from the membranes surrounding the brain and spinal cord. They are more common in women and tend to occur in middle-aged and older adults.

Implications

The updated safety warnings on MPA products may change how patients and providers assess risks and benefits. While MPA’s benefit-risk profile is still favorable, the added meningioma risk could, therefore, affect treatment decisions. This may lead to higher monitoring costs and revised treatment plans. Moreover, healthcare systems may need more resources to monitor and manage potential meningioma cases. As a result, this could strain budgets and impact resource allocation. Additionally, patient compliance might decline if concerns about side effects grow. Consequently, clear education and counseling will be vital to keep patients on treatment.

Furthermore, enhanced reporting of adverse reactions is essential to track meningioma cases linked to MPA. Stronger pharmacovigilance practices will, in turn, improve safety and management. Overall, SAHPRA’s update reinforces the need for active monitoring and safety measures. These efforts ensure safer treatments and better health outcomes.

Reference url

Recent Posts

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.